NCT05872724RecruitingPhase 2
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
Clinical Study on Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD
Source: ClinicalTrials.gov · Last updated 24 May 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 12 Apr 2023
- Start date
- 16 Jan 2023
- Primary completion date
- 16 Jan 2028
- Lead sponsor
- Suzhou Municipal Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT05872724
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 32
- From 16 Jan 2023 to the primary completion date, 16 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Suffering from other malignant tumors.
- Do not receive the specified treatment or change the treatment regimen before the disease progresses.
- Have an autoimmune disease.
Other
- The study cannot be followed up according to the defined clinical follow-up period.
- Unable to accept or provide CT or other designated therapeutic evaluation means.
Who the study is looking for
- Patients with histopathological and clinical (FIGO 2018) stage ⅠB2 \~II A2 cervical cancer.
- Above the age of 18.
- General status: ECOG score 0-2.
- Be able to understand the research scheme, voluntarily participate in the study, and sign the informed consent.
- Good compliance, able to cooperate with the collection of specimens at each node and provide corresponding clinical information.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Affiliated Suzhou Hospital of Nanjing Medical University Coordinator of this site? Confirm its status | Suzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.